Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Nicollet Investment Management Inc.

Nicollet Investment Management Inc. decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.8% during the 4th quarter, Holdings Channel reports. The institutional investor owned 5,767 shares of the medical research company’s stock after selling 225 shares during the period. Nicollet Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $3,000,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TMO. HighPoint Advisor Group LLC lifted its position in Thermo Fisher Scientific by 0.4% in the fourth quarter. HighPoint Advisor Group LLC now owns 11,949 shares of the medical research company’s stock worth $6,491,000 after purchasing an additional 53 shares during the period. Family Legacy Inc. boosted its stake in Thermo Fisher Scientific by 5.8% during the fourth quarter. Family Legacy Inc. now owns 2,664 shares of the medical research company’s stock valued at $1,452,000 after buying an additional 147 shares in the last quarter. Rodgers Brothers Inc. grew its holdings in Thermo Fisher Scientific by 1.8% during the fourth quarter. Rodgers Brothers Inc. now owns 2,119 shares of the medical research company’s stock worth $1,102,000 after acquiring an additional 37 shares during the period. Seven Mile Advisory lifted its holdings in Thermo Fisher Scientific by 23.2% in the 4th quarter. Seven Mile Advisory now owns 696 shares of the medical research company’s stock valued at $362,000 after acquiring an additional 131 shares during the last quarter. Finally, Prudent Man Investment Management Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $93,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on TMO. UBS Group lifted their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Wells Fargo & Company boosted their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Raymond James reiterated an “outperform” rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Citigroup reduced their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Four analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Trading Down 0.4 %

Shares of TMO stock opened at $498.05 on Tuesday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 1 year low of $484.27 and a 1 year high of $627.88. The firm’s fifty day simple moving average is $540.37 and its 200 day simple moving average is $551.02. The firm has a market capitalization of $187.89 billion, a P/E ratio of 30.13, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.35%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.41%.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.